Machelle Manuel, Ph.D., Joins Amylyx Pharmaceuticals as Vice President, Head of Global Medical Affairs

New Vice President of Medical Affairs Brings 20+ Years of Experience to Growing Leadership Team Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Machelle Manuel, Ph.D., as Vice President, Head of Global Medical Affairs. Dr. Manuel brings more than 20 years of experience in medical scientific affairs in the pharmaceutical industry. “It is our great pleasure to welcome Dr. Manuel to Amylyx as we continue our quest to end suffering caused by neurodegenerative diseases,” said Patrick Yeramian, M.D., MBA, Chief Medical Officer at Amylyx Pharmaceuticals. “Machelle brings an impressive and unique skillset and leadership qualities that will further poise Amylyx to grow from a clinical- to commercial-stage company.” Previously, Dr. Manuel spent eight years at Ironwood Pharmaceuticals, where she was head of global medical scientific affairs

Amylyx Pharmaceuticals Gets #INKEDforALS

Company Launches #INKEDforALS Campaign in its Commitment to Raising Awareness for the ALS Community During ALS Awareness Month Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today is honored to support ALS Awareness Month 2020 with the launch of “#INKEDforALS”, a campaign that aims to raise awareness for ALS. The campaign will serve as a platform to bring people together to educate and encourage conversation about ALS and celebrate the efforts of the caregivers and physicians who are fighting alongside people with ALS. In support of this year’s ALS Awareness Month, Amylyx created a temporary tattoo to raise awareness and funds, spark conversation about ALS and rally this resilient community together to help fight the disease. To help take action alongside this effort, Amylyx is encouraging the community to: Order a temporary tattoo from www.INKEDforALS.com Apply

European Medicines Agency Grants Orphan Drug Designation to Amylyx Pharmaceuticals’ AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that AMX0035 be designated as an orphan medicinal product for the treatment of ALS. AMX0035 is an investigational, first-in-class, disease-modifying therapy designed to reduce neuronal death and dysfunction. The EMA grants Orphan Drug Designation status for products intended for the treatment, prevention or diagnosis of rare, life-threatening or chronically debilitating conditions where the product may represent a significant benefit over existing treatments. “ALS patients worldwide are in need of new therapies,” said Joshua Cohen, Co-CEO, Chairman, and Co-Founder of Amylyx, “We’re excited about today’s news and look forward to working with the European Medicines Agency on the next steps for

Amylyx Pharmaceuticals Appoints Jeffrey Trigilio Chief Financial Officer

New Chief Financial Officer Brings Expertise in Business Development and Pipeline Diversification Planning Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Jeffrey Trigilio as the company’s first Chief Financial Officer. In this new role, Jeff will lead the company’s financial strategy and business growth and development. Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Amylyx, Jeff most recently served as Vice President of Finance at BlueRock Therapeutics, an engineered cell therapy company focused on neurology, cardiology and immunology with a lead program in Parkinson's disease. While there, he oversaw the finance department and served on BlueRock’s Leadership Team. Jeff helped develop BlueRock’s capital

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial

Study Meets Primary Endpoint of Slowing of ALS as Measured by the ALSFRS-R December 17, 2019 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M. Healey & AMG Center for ALS at Mass [...]

Amylyx Announces Appointment of Debra Canner as Global Head of Human Resources

Passionate HR Leader Brings 20+ Years of Experience to Solidify the Growth of the Company’s Team December 12, 2019 09:30 AM Eastern Standard Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first Global Head of Human Resources. Deb will serve on Amylyx’ Executive Team, overseeing the [...]

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

October 04, 2019 12:50 PM Eastern Daylight Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and [...]

Amylyx Pharmaceuticals Strengthens Leadership Team with the Appointments of Chief Medical Officer, Chief Commercial Officer and Global Head, Supply Chain

June 24, 2019 10:46 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., today announced three additions to its executive leadership team, appointing industry veterans Patrick Yeramian, M.D., MBA, as chief medical officer, Margaret Olinger, MBA, as chief commercial officer and Tom Holmes as global head, supply chain. These three key appointments serve [...]

Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial

April 03, 2019 08:30 AM Eastern Daylight Time CAMBRIDGE, MA (BUSINESS WIRE) — Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its first patients in a recently expanded Phase 2 clinical trial (PEGASUS) to assess AMX0035 in individuals with Alzheimer’s [...]

Load More Posts